AG
AKRO

Algert Global’s Akero Therapeutics AKRO Stock Holding History

Algert Global’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,919
Closed -$1.17M – 1122
2025
Q2 		$1.17M Sell
21,919
-53,010
-71% -$2.41M 0.02% 773
2025
Q1 		$3.03M Buy
74,929
+15,195
+25% +$644K 0.08% 457
2024
Q4 		$1.66M Sell
59,734
-8,318
-12% -$252K 0.04% 667
2024
Q3 		$1.95M Buy
68,052
+5,191
+8% +$135K 0.05% 558
2024
Q2 		$1.48M Sell
62,861
-24,562
-28% -$525K 0.05% 564
2024
Q1 		$2.21M Buy
87,423
+38,873
+80% +$934K 0.09% 383
2023
Q4 		$1.13M Buy
48,550
+37,776
+351% +$745K 0.05% 587
2023
Q3 		$545K Sell
10,774
-11,790
-52% -$549K 0.03% 714
2023
Q2 		$1.05M Hold
22,564
– – 0.05% 643
2023
Q1 		$863K Buy
22,564
+8,656
+62% +$386K 0.04% 687
2022
Q4 		$762K Buy
+13,908
New +$596K 0.04% 676

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's AKRO Position: Q3 2025 in Review

Algert Global sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 21,919 shares — an estimated $1.17M sold.

Algert Global first reported a position in AKRO in Q4 2022 and held it in 11 quarters. The position peaked at $3.03M in Q1 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Algert Global reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 21,919 Akero Therapeutics shares in Q3 2025, an estimated $1.17M.
  • Algert Global first reported a position in Akero Therapeutics in Q4 2022 and held it in 11 quarters.
  • Algert Global's Akero Therapeutics position peaked at $3.03M in Q1 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.